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Abstract 
Histatins are a family of histidine-rich peptides that are found in saliva. This 
family of peptides has antifungal properties. In this family, histatin 5 is the most efficient 
antifungal peptide against Candida albicans. The mechanism for the antifungal activity of 
histatin 5 is still unknown. Previous studies suggest that the metal-binding properties of 
histatin 5 may have some connection to its antifungal activity. Although there is some 
evidence that histatin 5 can bind Cu(II), currently there is no conclusive data on the Cu(I) 
binding properties of histatin 5. This work focuses on investigating the copper-binding 
properties of histatin 5 and analyzing the role these copper-binding properties may play 
in the antifungal activity of histatin 5. Model peptides of histatin 5 have been 
synthesized and copper binding studies were performed by UV-Vis spectroscopy and 
mass spectrometry. Reactive oxygen species formation process was studied by 
fluorescence assay.  
 
 
  
v 
Contents 
Abstract ......................................................................................................................................... iv 
List of Tables .............................................................................................................................. viii 
List of Figures ............................................................................................................................... ix 
Acknowledgements ..................................................................................................................... xi 
1. Introduction ............................................................................................................................... 1 
1.1 Fungal infection and antifungal drugs .......................................................................... 1 
1.2 Antifungal peptide: histatin 5 ......................................................................................... 2 
1.3 Possible antimicrobial mechanism of histatin 5 ........................................................... 3 
1.4 Metals and histatin 5 ........................................................................................................ 5 
1.5 Statement of objectives .................................................................................................... 7 
2. Spectroscopic studies of copper binding of histatin 5 model peptides ............................. 8 
2.1 Background and significance .......................................................................................... 8 
2.2 Results ................................................................................................................................ 9 
2.2.1 Model peptide design ................................................................................................. 9 
2.2.2 Cu(II) binding study ................................................................................................. 11 
2.2.3 Cu(I) binding study ................................................................................................... 14 
2.3 Summary .......................................................................................................................... 18 
2.4 Materials and methods .................................................................................................. 19 
3. Investigate the solution conditions that favor the 390 nm spectral feature .................... 22 
3.1 Background and significance ........................................................................................ 22 
  
vi 
3.2 Results .............................................................................................................................. 23 
3.2.1 The effect of copper concentration .......................................................................... 23 
3.2.2 Generation of new species requires oxidizing agents .......................................... 26 
3.2.3 The effect of ascorbic acid ........................................................................................ 28 
3.2.4 The effect of different reducing agents ................................................................... 31 
3.2.5 The effect of component concentrations ................................................................ 33 
3.2.6 Analysis of peptide-copper binding by the oxidation of ascorbic acid ............. 34 
3.3 Mass spectral analysis of Cu-peptide-ascorbic acid reactions ................................. 36 
3.3.1 LC-MS results ............................................................................................................. 36 
3.3.2 MALDI study ............................................................................................................. 39 
3.4 Summary .......................................................................................................................... 41 
3.5 Material and methods .................................................................................................... 44 
4. Study of reactive oxygen species in vitro ............................................................................ 46 
4.1 Background and significance ........................................................................................ 46 
4.2 Results .............................................................................................................................. 47 
4.2.1 Introduction of DCF assay ....................................................................................... 47 
4.2.2 Comparison of histatin model peptides ................................................................. 47 
4.2.3 Comparison of different reducing agents .............................................................. 50 
4.3 Summary .......................................................................................................................... 51 
4.4 Materials and methods .................................................................................................. 53 
5. Conclusion ............................................................................................................................... 55 
Appendix A.................................................................................................................................. 56 
  
vii 
References .................................................................................................................................... 60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
viii 
List of Tables 
Table 1: Amino acid sequences of major histatins. (Sp represents a phosphoserine 
residue) ........................................................................................................................................... 3 
Table 2: Names and sequences of synthesized peptides*...................................................... 10 
Table 3: MALDI result of ATCUN-HH with different concentration of Cu(II) in the 
presence of excess ascorbic acid.* ............................................................................................. 39 
Table 4: MALDI result for different peptide with Cu(II) and ascorbic acid* ..................... 40 
Table 5: MALDI result for different peptide with Cu(II) and sodium dithionite*............. 41 
 
 
 
  
ix 
List of Figures 
Figure 1: General structure of ATCUN-Cu(II) complex. ......................................................... 6 
Figure 2: UV-Vis spectra of peptide-Cu(II) complexes. ......................................................... 11 
Figure 3: UV-Vis spectra of peptides with 1 equiv CuSO4 (0.3 mM) and 1 mM ascorbic 
acid in 50 mM HEPES buffer. .................................................................................................... 13 
Figure 4: Structure of BCS, BCA, ferrozine (Fz) ...................................................................... 14 
Figure 5: Different peptides compete with Fz for Cu(I) in glove box. ................................. 16 
Figure 6: UV-Vis spectra of ATCUN-HH peptide with different concentration of Cu(II) 
in the presence of excess of ascorbic acid. ............................................................................... 25 
Figure 7: UV-Vis spectra of ATCUN-HH peptide, Cu(II) and excess ascorbic acid in 
anaerobic conditions and aerobic conditions. ......................................................................... 26 
Figure 8: UV-Vis spectrum of ATCUN-HH, Cu(II) with excess ascorbic acid and H2O2 in 
anaerobic conditions. .................................................................................................................. 27 
Figure 9: UV-Vis spectra of ATCUN-HH with Cu(II) in the presence of excess H2O2 in 
anaerobic and aerobic conditions. ............................................................................................ 29 
Figure 10: UV-Vis spectra of ATCUN-HH and Cu(I) upon addition of H2O2 and O2. ..... 30 
Figure 11: Changes of UV-Vis absorption at 388 nm overtime of ATCUN-HH, Cu(II) in 
the presence of different concentrations of ascorbic acid. ..................................................... 31 
Figure 12: UV-Vis spectra of peptide, Cu(II) in the presence of excess sodium dithionite.
 ....................................................................................................................................................... 33 
Figure 13: UV-Vis spectrum of ATCUN-HH and Cu(II) in the presence of excess ascorbic 
acid. ............................................................................................................................................... 34 
Figure 14: Copper catalyzed ascorbate oxidation. [34, 41] .................................................... 35 
Figure 15: UV-Vis absorbance changes at 265 nm of 0.1 mM ascorbic acid with different 
peptides and Cu(II) in aerobic conditions, pH=7.4. ............................................................... 35 
  
x 
Figure 16: LC-MS result of ATCUN-HH with Cu(II) in 50 mM HEPES buffer pH=7.4. ... 37 
Figure 17: LC-MS result for ATCUN-HH and Cu(II) in the presence of 1 mM ascorbic 
acid in 50 mM HEPES buffer pH=7.4. ...................................................................................... 38 
Figure 18: A) Structure of BA.[42]  B) UV-Vis spectrum of the generation of BACu(II)-
OOH.[42] ...................................................................................................................................... 42 
Figure 19: Hypothesis of the formation of new species which has absorbance at 390 nm.
 ....................................................................................................................................................... 44 
Figure 20: Mechanism of DCF assay. ....................................................................................... 47 
Figure 21: Fluorescence intensity of DCF recorded 2 h after reacting model peptides, 
Cu(II) and H2DCF in the presence of excess ascorbic acid. .................................................. 48 
Figure 22: Fluorescence intensity of DCF recorded 2 h after reacting model peptides, 
Cu(II) and H2DCF in the presence of excess sodium dithionite. ......................................... 50 
 
 
 
 
 
 
 
 
 
 
 
  
xi 
Acknowledgements 
I am grateful to many people including my advisor, my parents, friends, lab 
colleagues and my committee members. First, I want to thank my advisor Katherine 
Franz for her support and guidance during these three years. She is a very nice advisor 
and I learnt a lot from her both about chemistry and the attitude for life. I also thank Dr. 
Wang and Dr. Fitzgerald. I acquired lots knowledge from their classes and also benefit a 
lot during the preliminary exam. In addition, I also thank Dr. Dubay, he gave me LC-MS 
training and offer lots help for my project.  
I would like to thank my colleagues at Franz lab including Qin, David, Mark, 
Andy, Marian, Drew and Bruno. They helped me a lot in the past three years. In 
particular, Mark and Drew taught me about the peptide synthesis which I know little 
before joining the group. Our postdoc Bruno also taught me a lot about copper binding 
study which help me solve the problem about the Cu(I) binding with histatin 5. Qin and 
David also helped me a lot during my preliminary exam.  
I owe thanks to my parents. They always respect my decision and give me 
freedom to choose the life I like. I also thank my boyfriend Zhiyuan Jin who always give 
me support when I encountered difficulty in study. 
I want to thank lots of my friends at Duke who make my life more enjoyable in 
the past three years. In particular, I would like to thank Qin Wang, who is a very nice 
person. We also have a very happy life in Duke, I think I am very lucky met her in Duke.   
  
xii 
I also thank the students in Fitzgerald lab, Yingrong Xu and Jagat who helped me 
a lot for my project. They are very nice and taught me lots knowledge about MALDI and 
MS/MS. 
At last, I am truly grateful to all of you! 
 1 
1. Introduction  
1.1 Fungal infection and antifungal drugs 
Fungal infections have become a threat to human life and the occurance of these 
infections has been increased over the years.[1] Fungal infections can occur in any part 
of human body including eyes, nails, skin, alimentary tract, or can be systemic. [1, 2] 
Anyone can suffer from fungal infections, however, the elderly or individuals who have 
a weakened immune system such as HIV patients are more likely to get infected.[1] 
Among the fungi which can cause fungal infections, Candida albicans is the species which 
leads to most of the fungal infections.[1, 3] Candida albicans is a yeast which commonly 
exist in humans. Their proliferation is restricted by the human immune system and 
other microorganisms. However, when the host immune defense system is 
compromised it becomes pathogenic.[4, 5]  
 Generally, antifungal drugs are targeted ergosterol.[6] As the major sterol of the 
fungal plasma membrane, ergosterol is significant for the cellular functions.[6, 7] The 
fluidity and integrity of the membrane requires ergosterol. In addition, ergosterol is also 
required for membrane bound enzymes to perform proper functions such as chitin 
synthetase, which plays a major role in cell wall biogenesis. [6]  
There are two classes of drugs used to treat fungal infections, the polyenes and 
the azole-based drugs.[1, 6, 7] The polyenes such as amphotericin B and nystatin are 
target membranes containing ergosterol. Compared to cholesterol-containing 
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membranes, polyenes have a greater activity for ergosterol-containing membranes.[6] 
Studies show that these drugs can intercalate into membranes, forming channels that 
allow potassium ions to leak out of the cell, and destroying the proton gradient across 
the membrane. [6] The azole-based drugs including imidazoles and triazoles target 
lanosterol demethylase in the ergosterol biosynthesis pathway.[6, 7] However, there are 
problems with these antifungal drugs. Amphotericin B is the most effective antifungal 
agent, but it is toxic to human body. [1, 6] Some azole-based drugs can cause liver 
damage and endocrinological disorders.[1, 6, 8] In addition, the long term use of azole-
based drugs to treat fungal infections has led to the emergence of many azole resistant 
strains.[8] Therefore, the investigation of new antifungal agents is significant.  
1.2 Antifungal peptide: histatin 5 
Several peptides and proteins with crucial antifungal properties have been 
studied such as cathelicidins, defensins and lactoferricins.[3, 6, 9] Among these are 
histatins: a family of low molecular weight, cationic, histidine-rich salivary peptides 
secreted by the parotid and submandibular glands.[10] The entire family of histatin 
peptides is encoded by only two human genes HTN1 and HTN2, and the products of 
these two genes are histatin 1 and histatin 3 (Table 1).[10, 11]  
Histatin 1 has 38 amino acids with Ser-2 phosphorylated, while histatin 3 is 
composed of 32 amino acids. Histatin 1 and histatin 3 have similar amino acid 
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sequences.[10] The peptides in the histatin family are derived from histatin 1 and 
histatin 3 by specific proteolytic processes. [12] 
Table 1: Amino acid sequences of major histatins. (Sp represents a 
phosphoserine residue)  
Histatin 1           DSPHEKRHHGYRRKFHEKHHSHREFPFYGDYDSNYLYDN 
Histatin 3           DS HAKRHHGYKRKFHEKHHSHRGYRSNYLYDN 
Histatin 5           DS HAKRHHGYKRKFHEKHHSHRGY 
 
The histatin peptide with the most potential to be an antifungal agent is histatin 5, 
which consists of the first 24 amino acids of histatin 3 and has the highest killing activity 
against Candida albicans at physiological concentrations (15-30 µM).[10, 13] Histatin 1, 
histatin 3, and histatin 5 constitute 85-90% of all histatin peptides in human saliva and 
histatin 5 is present at the highest concentration.[10, 11, 13, 14] Histatin 5 is also known 
to have antifungal activity against other fungi such as Candida glabrata, Saccharomyces 
cerevisiae and Cryptococcus neoformans.[14] Considering the significant antifungal activity 
of Histatin 5 and its non-toxic to humans, it is promising to investigate antifungal agents 
based on histatin 5. 
1.3 Possible antimicrobial mechanism of histatin 5 
Even though the antifungal and antibacterial properties of the histatin peptides 
have been proven, the underlying mechanisms of action for histatin 5 are still unclear. 
The elucidation of the antifungal mechanism of histatin 5 could provide some new ideas 
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for the design of antifungal drugs. For most antifungal peptides, the generation of 
helical conformations in hydrophobic environments is crucial in their antifungal 
mechanisms.[9, 15, 16] Histatin 5 however is not act in this same way.[17] The proposed 
mechanism for the antifungal activity of histatin 5 is a multistep process, which includes 
damaging the cell membrane, disrupting the electron transport chain and generating 
reactive oxygen species (ROS).[11, 18-21]  
Although the exact antifungal mechanism of histatin 5 is not identified, it has 
been proposed that in order to kill the yeast, histatin 5 must first interact with and pass 
through the cell wall.[11, 22-24] However, there is no conclusive information on how 
histatin 5 interacts with the cell wall, even though one study suggests that histatin 5 
binds to the heat shock protein Ssa1/2 on the cell surface and then can be transported 
into the cell. [22, 23, 25] In addition, the exact intracellular target of histatin 5 is also 
unknown. One hypothesis is that histatin 5 targets the yeast mitochondria.[19, 20, 26] A 
previous study shows that non-respiring yeast cells are insensitive to histatin 5 which 
suggests that mitochondria may be crucial for the performance of the antifungal activity 
of histatins.[20] An early report suggests that after histatin 5 is transported to the cytosol 
it enters the mitochondria and interacts with coenzyme Q leading to the production of 
ROS in the electron transport chain which subsequently kills the yeast.[11, 20] In 
addition, the interaction between histatin 5 and the mitochondria can also induce the 
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release of ATP into the cytoplasm which is proposed to be able to activate membrane 
ATP receptor and kill the yeast.[21] [2, 27] 
Moreover, one mutant peptide of histatin 5, ATCUN-C16 
(DSHAGYKRKFHEKHHSHRGY) has been synthesized and studied. The result shows 
that except for antifungal activity, this ATCUN-C16 peptide also has nuclease activity 
when copper, zinc ions and ascorbic acid are present.[28] This nuclease activity of 
ATCUN-C16 peptide may be due to the oxidative activities of the Cu-ATCUN 
complex.[28] This could be related to the proposed mechanism that histatin 5 disturbs 
the cell cycle by down-regulation of the expression of some proteins which participate in 
cell cycling.[2, 29] This oxidative nuclease activity in the presence of Cu(II) suggests a 
possible role of metal ions in the antifungal properties of histatin peptides.[28, 29] 
1.4 Metals and histatin 5 
Histatin 5 contains a zinc-binding motif His-Glu-X-X-His and an ATCUN (amino 
terminal Cu(II) and Ni(II)) motif.[30, 31] An ATCUN motif is a metal-binding amino acid 
sequence that exists in a variety of Cu(II)- and Ni(II)-binding proteins, such as 
albumins.[32, 33]The general structure of the ATCUN motif is H2N-X-X-His where X 
represents any amino acid except proline.[32, 33] The N-terminus amino group, the 
imidazole nitrogen of histidine and the two backbone nitrogens are involved in Cu(II) 
binding (Figure 1).[32, 33] In histatin 5, the ATCUN motif is the first three amino acids 
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(H2N-Asp-Ser-His) at the N-terminus. Previous studies show that histatin 5 has a high 
affinity for Cu(II) (K= 2.6×107 M-1) at  the ATCUN site.[28, 31]  
 
Figure 1: General structure of ATCUN-Cu(II) complex.  
ATCUN motifs bind with Cu(II) using the lone pair of electrons on the imidazole 
nitrogen of histidine, the two backbone nitrogens and the N-terminus amino group. 
 
How Cu(II) participates in the antifungal activity of histatin peptides is currently 
unknown. Copper is vital to many cellular metabolic processes including pigmentation, 
antioxidant activity and cell proliferation. Cellular uptake of copper in eukaryotes is 
achieved by the copper transport (CTR) proteins.[34] Previous data in the Franz lab 
show that the histidine residues in the human Ctr1 sequence play an important role in 
copper uptake.[34] The first 14 amino acids of human Ctr1 (MDHSHHMGMSYMDS) 
have a high affinity for both Cu(II) and Cu(I).[34] The Cu(II) binding site of Ctr1 is an 
ATCUN site (H2N-Met-Asp-His); whereas the Cu(I) binding site is the two His-His 
residues with an additional histidine or methionine.[34] Considering that histatin 5 is 
also a histidine rich peptide that has an ATCUN motif (H2N-Asp-Ser-His) and an 
adjacent His-His site, the similarities between human Ctr1 peptide and histatin 5 are 
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interesting. In addition, despite the difference of the environment of these two peptides, 
it is attractive to study how the sequence of these two peptides affects the copper 
binding property and leading to their quite different functions.  
1.5 Statement of objectives 
Previous studies in our lab suggest that human Ctr1 can bind with Cu(II) and 
Cu(I).[34] Early studies show that histatin 5 has a high affinity for Cu(II), but there are 
no clear studies related to its Cu(I) binding. Considering that metal-ion binding may be 
related to the antifungal properties of histatin 5, analysis of the Cu(II) and Cu(I) binding 
properties of histatin 5 may give us a new understanding about the mechanism of its 
antifungal activity.  
The goal for this project is to study the copper binding properties of histatin 5 
and analyze the role this copper binding property plays in the antifungal activity of 
histatin 5. Here, a series of histatin 5 derivatives containing the first 11 amino acids have 
been constructed and studied. Cu(II) and Cu(I) binding studies were performed by UV-
Vis spectroscopy and mass spectrometry. In addition, ROS formation was been 
investigated.
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2. Spectroscopic studies of copper binding of histatin 5 
model peptides 
2.1 Background and significance 
Due to the diminishing effectiveness of antifungal drugs, the rate of fungal 
infections is increasing. Candida albicans is a genus of yeast that causes most human 
fungal infections.[1, 6] The increasing resistance of fungal strains to antifungal drugs 
raises the need for new antifungal agents. Based on these reasons, histatin 5, which 
exists in human saliva and has significant killing activity to Candida albicans, has been 
noticed.  
It is known that the metal binding properties of histatin 5 may relate to its 
antifungal activity.[29-31] Histatin peptides have the potential to complex with metal 
ions.[35] Histatin 5 contains a zinc-binding motif and an ATCUN motif resulting in a 
high affinity for Zn(II) and Cu(II).[30, 31] In addition, histatin 5 also can bind with Ni(II), 
Ca(II) and Fe(II).[30, 31] The order of metal binding affinity to histatin 5 is 
Cu(II)>Ni(II)>Zn(II) in aqueous solution whereas Ca(II) and Fe(II) can only weakly 
bound to histatin 5.[31] 
It is known that histatin 5 can bind with Cu(II) and has an absorbance band at 
525 nm which is the typical Cu(II)-ATCUN peak.[32, 33] It is also reported that a short 
ATCUN-containing synthetic model peptide of histatin 5 has pro-oxidant activity.[29] It 
was speculated that this formation of ROS by Cu(II) and histatin 5 may contribute to its 
antifungal mechanism.[29] 
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 While Cu(II) binding has been documented for histatin 5, there are no reported 
studies related to its Cu(I) binding. The goal of this chapter is to study the Cu-binding 
properties of synthetic peptides corresponding to the histatin peptides sequence. Here, a 
series of histatin 5 derivatives composed of the first 1-11 residues of the native peptide 
have been investigated, specifically with regards to the importance of each histidine for 
Cu(II) and/or Cu(I) binding. UV-Vis spectroscopy is used to study Cu(II) and Cu(I) 
binding.  
2.2 Results 
2.2.1 Model peptide design 
Model peptides of the first 11 amino acids of histatin 5 were prepared on a 
peptide synthesizer by using Fmoc-based solid-phase peptide synthesis methodology 
and purified by HPLC. ATCUN-HH contains the first 11 residues of histatin 5 plus a 
tryptophan at the C-terminus which provides a chromophore for accurate determination 
of peptide concentration by absorption spectroscopy.  To determine the amino acids that 
are important for copper binding, histidine residues in the ATCUN-HH peptide were 
systematically substituted for alanine. The peptide in which two histidines in positions 7 
and 8 are replaced by alanine is called H7A/H8A, whereas peptides with a single 
histidine replaced at position 3, 7 or 8 are called H3A, H7A and H8A, respectively. 
Histatin 8 is the last 12 residues of histatin 5, however, the distance between the ATCUN 
motif and the His-His site in histatin 8 is shorter than the ATCUN-HH peptide. Histatin 
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8 was synthesized to identify whether this will affect the copper binding property of the 
peptide. F9AA contains the first nine amino acids of histatin 5, and notably contains no 
tyrosine or tryptophan residues. 
Table 2: Names and sequences of synthesized peptides* 
Peptide name Amino acid sequence 
ATCUN-HH D-S-H-A-K-R-H-H-G-Y-K-W 
H7A D-S-H-A-K-R-A-H-G-Y-K-W 
H3A D-S-A-A-K-R-H-H-G-Y-K-W 
H7A/H8A D-S-H-A-K-R-A-A-G-Y-K-W 
H8A D-S-H-A-K-R-H-A-G-Y-K-W 
F9AA                              D-S-H-A-K-R-H-H-G 
Ctr1                              M-D-H-S-H-H-M-G-M-S-Y-M-D-S 
Histatin 8                              K-F-H-E-K-H-H-S-H-R-G-Y 
* All peptides prepared as the free amine at the N-terminus (H2N) and C-
terminal amide. 
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2.2.2 Cu(II) binding study 
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Figure 2: UV-Vis spectra of peptide-Cu(II) complexes.  
Absorbance spectra of 0.3 mM model peptides (ATCUN-HH, H7A, H7A/H8A, 
H3A, H8A, F9AA and histatin 8) with 1 equivalent of CuSO4 at pH 7.4 in 50 mM HEPES 
buffer. The peptides that have an ATCUN motif show a Cu(II)-ATCUN absorbance band 
near 525 nm. 
 
A previous report shows that histatin 5 has a high affinity for Cu(II) (K= 2.6×107 
M-1).[30, 31] In order to confirm that the first 11 amino acids of histatin 5 also have this 
property, Cu(II) binding of the model peptides was investigated by UV-Vis 
spectroscopy. Figure 2 shows the spectrum for the model peptides with Cu(II) in 50 mM 
HEPES buffer at pH 7.4. The ATCUN-HH peptide with CuSO4 has an absorbance band 
near 525 nm which is characteristic of an albumin-like distorted square planar 
coordination environment with Cu(II).[32] Substitution of the histidine at the seventh or 
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eighth position causes no significant change in the peptide-Cu(II) spectrum (Figure 2). 
This indicates that neither the histidine residue in position 7 nor 8 are participate in the 
Cu(II) binding. In contrast, replacement of histidine in the third position such as in the 
H3A peptide results in an absorbance shift, suggesting that the coordination 
environment is different in this mutant peptide. The Cu(II)-histatin 8 and Cu(II)-F9AA 
spectra also show an absorbance near 525 nm because these two peptides also have an 
ATCUN motif. This data indicates that the model peptides containing an ATCUN motif 
can bind Cu(II). This finding is consistent with previous studies that the ATCUN motif 
of histatin 5 has a high affinity for Cu(II). 
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C                                                                     D 
Figure 3: UV-Vis spectra of peptides with 1 equiv CuSO4 (0.3 mM) and 1 mM ascorbic 
acid in 50 mM HEPES buffer. 
A) Comparison of the changes in absorbance at 525 nm. B) ATCUN-HH + Cu(II) 
+ ascorbic acid. C) H7A/H8A + Cu(II) + ascorbic acid.  D) F9AA + Cu(II) + ascorbic acid. 
Spectrum A shows that the expected ATCUN-HH-Cu(II) absorbance band at 525 nm 
have nearly no change for the given model peptides when reducing agent present. There 
is a new peak generated near 390 nm after adding ascorbic acid to Cu(II)-ATCUN-HH 
and Cu(II)-F9AA solution. 
 
In order to verify whether a reducing agent will reduce Cu(II) to Cu(I) in the 
presence of model peptides, peptide-Cu(II) (1:1, 0.3 mM) solutions with excess ascorbic 
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acid (1 mM) in 50 mM pH 7.4 HEPES were monitored by UV-Vis spectroscopy. This 
experiment was conducted with ATCUN-HH, histatin 8, H7A, H7A/H8A, H8A, F9AA 
and Ctr1 peptide. 
Figure 3A shows that there is no significant change in the Cu(II)-ATCUN binding 
site for any of the histatin model peptides tested. This indicates that even with excess 
reducing agent present, the ATCUN motif of the peptides can still bind with Cu(II). 
However, the addition of ascorbic acid generates an obvious peak around 390 nm for the 
ATCUN-HH and F9AA peptide which is not expected for this experiment (Figure 3B, 
3D). This peak was not observed for H7A, H7A/H8A and H8A peptides. Also, the 
addition of excess ascorbic acid to the Ctr1-Cu(II) solution also did not produce an 
absorbance band  around 390 nm (Appendix A.1). Further studies need to be employed 
to verify which species leads to the observed absorbance band around 390 nm. 
2.2.3 Cu(I) binding study 
N
N
SO3
SO3
N
N
C
C
O
O
O
O
N
N
N
N
SO3
SO3
 
                   BCS                                            BCA                                        Fz 
Figure 4: Structure of BCS, BCA, ferrozine (Fz) 
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Directly determining Cu(I) binding affinity is often difficult. Therefore, Cu(I) 
colorimetric indicators such as BCS (2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline 
disulfonic acid, logβ2=19.8), BCA ( bicinchoninic acid, logβ2=14.7), and Fz (ferrozine, 
logβ2=11.6) are frequently used to obtain Cu(I) binding affinity by competition.[36-38] In 
this study, a first attempt was completed using BCA as a competitive ligand to study the 
Cu(I) binding of  model peptides. When adding Ctr1 to [Cu(I)(BCA)2]3- solution in a 
nitrogen-filled glove box, the absorbance of [Cu(I)(BCA)2]3- at 562 nm decreased 
(Appendix A.5). This result is consistent with our lab’s previous studies showing that 
this Ctr1 peptide can compete with BCA for Cu(I) binding.[34] However, for other 
model peptide of histatin 5, the affinity of BCA for Cu(I) is too high to allow effective 
competition. 
 The weaker ligand ferrozine (Fz) was then used as a competitive ligand to 
determine the Cu(I) binding property of model peptides. Fz is a well-known 
colorimetric indicator for Fe(II) which has also found utility as a Cu(I) colorimetric 
indicator.[36] The [Cu(I)(Fz)2]3- complex in solution has an absorbance band at 470 nm 
(ε= 4320 M-1cm-1).[36]  In this study, solutions of [Cu(I)(Fz)2]3- were titrated with up to 10 
equivalents of model peptides. 
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C                                                                  D 
Figure 5: Different peptides compete with Fz for Cu(I) in glove box. 
In this experiment, [Cu(I)(CH3CN)4]PF6 = 20 µM, Fz = 50 µM, 50 mM HEPES 
buffer pH=7.4. A) Ctr1 compete with Fz for Cu(I), tried 0.5, 1, 1.5, 2, 3, 5, 10 equivalents 
of Ctr1 peptide. B) ATCUN-HH compete with Fz for Cu(I), tried 1,5,10 equivalents of 
ATCUN-HH. C) H7A/H8A compete with Fz for Cu(I), tried 1,5,10 equivalents of 
H7A/H8A. D) Comparison the Cu(I) binding ability of model peptides. 
 
Previous data in our lab shows that the first 14 amino acids of the human Ctr1 
have a high affinity for Cu(I).[34] In this study we first tried this Ctr1 peptide to titrate a 
[Cu(I)(Fz)2]3- solution in nitrogen-filled glove box. As shown in Figure 5A, competition 
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can be observed by the decrease of absorbance at 470 nm with the addition of Ctr1 
peptide. There is a weak increase at 562 nm which indicates the formation of 
[Fe(II)(Fz)3]4- complex due to a small amount of residual Fe in the sample.[36] In 
addition, after adding 3 equivalents of Ctr1, the absorbance band at 470 nm disappeared 
which indicates that Ctr1 has a strong affinity for Cu(I), which corresponded to our 
previous study. 
In order to evaluate if the histidines in histatin 5 enable Cu(I) binding, ATCUN-
HH, H3A, H7A/H8A, H8A were tested in this competition assay. Figure 5D shows that 
ATCUN-HH, H3A and H8A can compete with Fz for Cu(I). However, after the addition 
of 10 equivalents of ATCUN-HH, H3A or H8A, the absorbance of [Cu(I)(Fz)2]3- at 470 nm 
has still not disappeared completely, as it had for Ctr1. This result indicate that Ctr1 has 
stronger Cu(I)-binding affinity than ATCUN-HH , H3A and H8A. Furthermore, the data 
plotted in Figure 5D reveals that the decrease in absorbance at 470 nm is more 
significant for the ATCUN-HH peptide than for either the H3A or H8A peptides which 
indicates that the Cu(I)-affinity of ATCUN-HH is greater than that of H3A or H8A. This 
finding suggests that all 3 histidines of the ATCUN-HH peptide contribute to the 
appreciable binding. 
Figure 5C shows that the addition of 10 equivalents of H7A/H8A cannot compete 
with Fz for Cu(I); the absorbance at 470 nm does not significantly change and the 
absorbance at 562 nm increases which is due to residual Fe present in the peptide 
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sample. Therefore, the substitution of any one of the three histidines in position 3, 7 or 8 
can reduce the Cu(I) binding affinity of ATCUN-HH. The remove of the two histidine 
residues in position 7 and 8 can lead to the complete loss affinity for Cu(I). Histidines are 
important for the Cu(I) binding of histatin 5 model peptides at pH 7.4.  
2.3 Summary 
In this study, UV-Vis spectra show that synthesized histatin 5 model peptides 
which contain an ATCUN motif can bind with Cu(II). This finding confirms the 
hypothesis that the ATCUN-HH peptide would bind Cu(II) similar to histatin 5. 
Moreover, with excess ascorbic acid present in the solution, the ATCUN-Cu(II) 
absorbance band at 525 nm has no significant changes which indicates that the ATCUN 
peptides can still bind with Cu(II) even in the presence of a strong reducing agent. 
Previous studies in our lab show that the histidine residues in Ctr1 play an 
important role in the interaction with Cu(I).[34] For histatin 5 model peptides, the result 
is similar. In this chapter it was shown that the histidine residues of that ATCUN-HH 
peptide has appreciable affinity for Cu(I). It is clear from the experiments discussed 
above that ATCUN-HH can bind both oxidation states of copper with significant affinity. 
In summary, this chapter provides direct evidence that model peptides of 
histatin 5 can form complexes with Cu(II) and Cu(I). These properties may be related to 
the established antifungal activity of histatin 5.  It is interesting that after adding excess 
ascorbic acid to an ATCUN-HH-Cu(II) solution, there is a new peak generated near 390 
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nm. The next chapter will describe a comprehensive study of the conditions that favor 
the formation of this new species. 
2.4 Materials and methods 
Reagent and method: 
Most of the reagents and solvents were purchased from Sigma Aldrich. Fmoc-
protected amino acids were purchased from Novabiochem and Chem-Impex 
International.  
Standard Fmoc-based solid-phase peptide synthesis strategy was used to 
synthesize model peptides on a Protein Technologies PS3 peptide synthesizer. A Waters 
Delta 600 HPLC equipped with a Water semi-preparative C-8 column was used to 
purify peptides. Lyophilization of all the model peptides was completed by using a 
Labconco Lyophilizer. Varian Cary 50 Conc UV-Visible spectrophotometer was used to 
collect all the UV-Vis absorbance data. LC/MS spectra were collected on an Agilent 1100 
Series spectrometer utilizing an electrospray ionization source coupled with an ion trap 
detector.  
Preparation of stock solution:  
CuSO4∙5H2O was dissolved in Nanopure water (18.0 MΩ) to get the Cu(II) stock 
solution, the concentration of Cu(II) stock solution was determined by EDTA 
(Ethylenediaminetetraacetic acid) titration to a murexide (Fischer) endpoint.  
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The peptide stock solutions were prepared by dissolving lyophilized peptide in 
Nanopure water (18.0 MΩ). The Edelhoch method was used to decide the concentrations 
of peptide solution.[39]  In general, peptide stock solution was added into 1 ml of 8 M 
Urea solution, the absorbance at 280 nm was monitored by UV-Vis spectroscopy. The 
extinction coefficients for tyrosine (ε=1490 M-1) and tryptophan (ε=5500 M-1) at 280 nm 
were used to calculate the concentration of peptide stock solution.[39]  
Synthesis 
Fmoc-PAL-PEG-PS resin (Applied Biosystems) was used to synthesis all the 
model peptides. Amino acid coupling was achieved by using HBTU ( O-benzotriazole-N, 
N, N’, N’-tetramethyluronium hexafluorophosphate; Novabiochem) and the coupling 
reagents (N-methylmorpholine (NMM) in N,N’-dimethylformamide ). Fmoc 
deprotection was achieved by using deprotection reagents which is 20% piperidine in 
DMF (v/v). After the peptide was synthesized by peptide synthesizer, the resin was 
washed by acetic acid, dichloromethane and methanol three times. 10 ml trifluoroacetic 
acid (TFA), 150 μl ethane dithiol (EDT), and 150 μl triisopropylsilane (TIS) were added 
to the resin and mixed for 4 hour under N2. 125-150 µ l of EDT and 125-150 µ l of 
bromotrimethylsilane (TMSBr) were added during the final 45 minutes. After this, N2 
was used to evaporate the TFA solution. When the volume of solution was less than 5 
mL, the peptides were washed by diethyl ether and centrifuged 3 times. Peptides were 
purified by HPLC on a C-8 column with a linear 40 minutes gradient from 0-60 % 
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acetonitrile in water with 0.1 % TFA. The purity of model peptides was verified by LC-
MS. 
Cu(I) binding study 
Cu(I) stock solutions were prepared by dissolving [Cu(CH3CN)4]PF6 in 
anhydrous acetonitrile in nitrogen-filled glove box. The concentration of Cu(I) stock 
solutions were determined spectrophotometrically by titration with excess BCA solution 
in the glove box. Cu(I)(BCA)2 has absorbance at 562 nm(ε=7900 M-1), and the absorbance 
data at 562 nm was used to calculate Cu(I) concentration.[34]  
Cu(I) competition assay was performed at pH 7.4 in 50 mM HEPES buffer, the 
concentration of Cu(I) was 20 µM and the concentration of ferrozine (Fz) was 50 µM. In 
this assay, the use of 1, 5, 10 equivalents of model peptides to compete with Fz is 
monitored by UV-Vis spectroscopy. If the peptide competes with Fz, the absorbance at 
470 nm will decrease. All the Cu(I) binding study were conducted in a nitrogen-filled 
glove box, and the solution were all deoxygenated. 
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3. Investigate the solution conditions that favor the 390 
nm spectral feature 
3.1 Background and significance 
Early studies of the metal-binding properties of histatin 5 revealed that it can 
bind with Zn(II), Cu(II) and Ni(II).[31] In the previous chapter, UV-Vis spectroscopy 
studies showed that model peptides that have an ATCUN motif can bind with Cu(II). 
This finding confirms the hypothesis that a shorter ATCUN-HH peptide binds Cu(II) in 
a similar fashion as the longer native histatin 5. In addition the Fz competition assay 
showed that ATCUN-HH can compete with Fz for Cu(I) and establishes that histatin 5 
peptides can bind with Cu(I). Therefore, it is clear that ATCUN-HH can bind Cu(II) and 
Cu(I), furthermore, all 3 histidine residues contribute to optimal competition with Fz for 
Cu(I). 
Because these model peptides can bind either oxidation state of copper, it would 
be interesting to study the reduction of Cu(II)-peptide complexes. It is important to note 
that when excess ascorbic acid is present, a new peak near 390 nm appears in the 
ATCUN-HH peptide/Cu(II) solution. This new peak is only formed for the ATCUN-HH 
and F9AA, no other histatin model peptides have this property. This result suggests that 
the sequence of the histatin 5 model peptide affects the redox properties of the peptide-
Cu(II) complexes. 
The cell space is a reducing environment replete with reducing agents including 
ascorbate, cysteine, and NADH. Copper ions could be acquired from a copper pool in 
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yeast mitochondria.[20, 29, 40] Considering in the presence of excess ascorbic acid, only 
the ATCUN-HH and F9AA peptides have this new absorbance at 390 nm. This new 
species may have some relationship with the antifungal activity of histatin 5. 
The aims for this chapter are to study the solution conditions and peptide 
sequences that favor observation of this 390 nm spectral feature formed in the reaction of 
ATCUN-HH with Cu(II) when excess ascorbic acid is present. UV-Vis spectroscopy and 
mass spectrometry methods were used in this chapter to interrogate the influence of 
factors such as oxygen, the effect of different reducing agent, the stoichiometry of 
peptide and Cu(II) on the formation of species formed at 390 nm.  
3.2 Results 
3.2.1 The effect of copper concentration 
The studies in chapter 2 show that a new peak near 390 nm formed in the 
solution containing excess ascorbic acid, ATCUN-HH and Cu(II). In order to elucidate 
which species lead to the formation of this peak we first want to know whether the ratio 
of peptide to Cu(II) will affect the absorbance at 390 nm. In this experiment, ATCUN-
HH peptide concentration was kept constant at 0.3 mM with 1 mM ascorbic acid, while 
the copper concentration varied from 0.5-2 equivalents of the peptide. Sample were 
prepared in 50 mM HEPES buffer pH=7.4. 
Figure 6 shows the UV-Vis spectra result when 1 mM ascorbic acid is combined 
with the peptides and 0.5, 0.6, 1, 2 equivalents of CuSO4. The sample of ATCUN-HH 
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peptide containing only 0.5 equivalents of Cu(II) do not develop an absorption peak at 
390 nm, although there is a slight increase in absorbance generally below 400 nm. In 
contrast, when the copper concentration is 0.8-1.5 equivalents of peptide, a distinct peak 
forms within minutes at λmax centered at 390 nm. This new feature grows in over the 
course of 1-2 hours and stabilizes at a similar intensity for these samples containing 0.8-
1.5 Cu(II) (Appendix A.3). The absorbance at 390 nm is much weaker when 0.6 
equivalents copper is present in the solution (Figure 6B). When the Cu(II) : ATCUN-HH 
ratio increases to 2:1, a distinct peak is not observed, although the intensity between 350-
500 nm increases generally (Figure 6D). 
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Figure 6: UV-Vis spectra of ATCUN-HH peptide with different concentration of Cu(II) 
in the presence of excess of ascorbic acid. 
ATCUN-HH = 0.3 mM, ascorbic acid = 1 mM, 50 mM HEPES buffer pH 7.4. A) 
0.5 equivalents of Cu(II), B) 0.6 equivalents of Cu(II) C) 1 equivalents of Cu (II) D) 2 
equivalents of Cu(II). The formation of the absorbance at 390 nm can be effected by the 
ratio of ATCUN-HH to Cu(II). 
 
These experiments show that the ratio of Cu(II) to ATCUN-HH peptide has some 
effect on the formation of the new peak near 390 nm, and that the formation of this 
feature is optimal when ratio of Cu : peptide close to 1.  
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3.2.2 Generation of new species requires oxidizing agents 
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Figure 7: UV-Vis spectra of ATCUN-HH peptide, Cu(II) and excess ascorbic acid in 
anaerobic conditions and aerobic conditions.  
ATCUN-HH peptide and Cu(II) concentration is 0.3 mM, ascorbic concentration 
is 1 mM, experiments performed in 50 mM HEPES buffer, pH=7.4. A) Experiment 
conducted in anaerobic conditions. B) Experiment conducted on the benchtop in aerobic 
conditions. The generation of the new peak at 390 nm requires the presence of oxygen. 
 
In order to test whether the formation of this new species requires oxygen, 
samples of peptide with equimolar CuSO4 and excess ascorbic acid were prepared in de-
oxygenated solvents and monitored spectrophotometrically in a nitrogen-filled 
anaerobic glove box. Figure 7 shows the comparison of this experiment conducted under 
anaerobic and aerobic conditions. In the absence of O2, the addition of 1 mM ascorbic 
acid does little to change the spectrum of the Cu(II)-peptide species (Figure 7A). Notably, 
no new feature appears at 390 nm, and the broad absorbance centered at 525 nm 
characteristic of Cu(II)-ATCUN species remains intact. However, in the presence of air, 
the peak at 390 nm readily forms upon mixing with 1 mM ascorbic acid (Figure 7B). 
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These experiments indicate that the generation of the new species at 390 nm requires 
oxygen.  
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Figure 8: UV-Vis spectrum of ATCUN-HH, Cu(II) with excess ascorbic acid and H2O2 
in anaerobic conditions. 
ATCUN-HH = 0.3 mM, Cu(II) = 0.3 mM, ascorbic acid = 1 mM, hydrogen 
peroxide concentration is 1 mM. Experiment was conducted in 50 mM HEPES buffer 
pH=7.4 in anaerobic conditions. 
 
In order to test whether other oxygen-containing species could facilitate 
formation of the 390 nm feature, 1 mM hydrogen peroxide and 1 mM ascorbic acid were 
added to ATCUN-HH/Cu(II) solution in 50 mM HEPES buffer in the nitrogen-filled 
glove box and monitored by UV-Vis spectroscopy. Figure 8 shows that after adding 
excess H2O2 and ascorbic acid a peak forms at 390 nm with an absorbance that grows in 
stronger than in samples that are prepared under ambient aerobic conditions (compare 
to Figure 6C for example). This experiment indicates that H2O2 can facilitate formation of 
the new species even in the absence of O2. Furthermore, the Cu-catalyzed aerobic 
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oxidation of ascorbic acid is known to generate H2O2 in situ, which suggest that H2O2 
may in fact be the active agent in the aerobic experiments as well. 
3.2.3 The effect of ascorbic acid 
The previous experiment clearly showed that H2O2 is capable of generating the 
390 nm feature from solutions of Cu(II) and ATCUN-HH peptide, at least in the 
presence of ascorbic acid. Several experiments were therefore conducted to test the 
dependence of these reactions on ascorbic acid. As shown in Figure 9A, the addition of 1 
mM H2O2 to 0.3 mM Cu(II)-ATCUN-HH under anaerobic conditions does not noticeably 
change the UV-Vis spectrum characteristic of the Cu(II)-ATCUN-HH species. When the 
same experiment is conducted under aerobic conditions (Figure 9B) a general and 
significant increase of absorbance grows in between 400-500 nm, indicative of some kind 
of non-specific reactivity. Although, a distinct feature at 390 nm is not apparent. The 
anaerobic experiment here is the most revealing, and suggests that H2O2 does not 
oxidizing or reduce the Cu(II) center complexed by ATCUN-HH and is not able to 
generate the 390  nm feature directly from reaction with the Cu(II) peptide. 
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Figure 9: UV-Vis spectra of ATCUN-HH with Cu(II) in the presence of excess H2O2 in 
anaerobic and aerobic conditions. 
ATCUN-HH = 0.3 mM, Cu(II) = 0.3 mM, H2O2= 1 Mm, 50 mM HEPES buffer pH 
=7.4. A) Experiment conducted in anaerobic conditions. B) Experiment conducted in 
aerobic conditions. 
 
The failure of H2O2 to generate the new peak at 390 nm without ascorbic acid 
present may be because the formation of the new peak requires a reducing agent to form 
Cu(I). In order to test this idea two experiments were conducted. The first was to add 
excess hydrogen peroxide to a Cu(I)-ATCUN-HH solution in anaerobic conditions, and 
the second was to make a Cu(I)-ATCUN-HH solution in the glove box then take the 
solution out and bubble oxygen into the solution. 
Figure 10A shows that the anaerobic addition of hydrogen peroxide or oxygen to 
solutions containing Cu(I)-ATCUN-HH solution generate two new features. A broad 
absorbance appears around 525 nm, which may be due to formation of Cu(II)-ATCUN, 
while a distinct peak at 350 nm concomitantly appears. However, this 350 nm feature 
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appears not the same as the 390 nm feature, its appearance indicates that Cu(I)-ATCUN-
HH does react directly with H2O2 to generate a new species. In contrast, exposure of 
Cu(I)-ATCUN-HH directly to O2 results only in the formation of the 525 nm feature 
indicative of Cu(II)-ATCUN, with no indication of an intermediate, at least under these 
timescales. While these combined results indicate that the generation of the 390 new 
species requires ascorbic acid, the direct reaction of Cu(I)-ATCUN-HH by H2O2 to 
generate a new species at 350 nm is interesting.  
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Figure 10: UV-Vis spectra of ATCUN-HH and Cu(I) upon addition of H2O2 and O2. 
 ATCUN-HH= 0.3 mM, Cu(I)= 0.3 mM, experiments conducted in 50 mM HEPES 
buffer, pH= 7.4. A) ATCUN-HH and Cu(I) in the presence of H2O2 in anaerobic 
conditions. B) ATCUN-HH-Cu(I) solution was made in glove box, after took it out from 
glove box bubbling oxygen to the solution. These experiments show that without 
ascorbic acid present in the solution, the peak at 390 nm cannot be formed.   
 
To further probe the ascorbic acid dependence on formation of the 390 nm peak, 
different concentrations of ascorbic acid were added to a Cu(II)-peptide. In this 
experiment, aliquots of 0.3 mM, 0.5 mM, 0.7 mM and 1 mM ascorbic acid were added to 
 31 
Cu(II)-ATCUN-HH solutions in aerobic conditions. Figure 11 shows that the absorbance 
band around 390 nm increased when the concentration of ascorbic acid increased. 
0 10 20 30 40 50 60 70
0.00
0.03
0.06
0.09
0.12
0.15
0.18
A
b
s
3
8
8
 n
m
Time (min)
 0.1 mM
 0.3 mM
 0.5 mM
 0.7 mM
 1 mM
 
Figure 11: Changes of UV-Vis absorption at 388 nm overtime of ATCUN-HH, Cu(II) 
in the presence of different concentrations of ascorbic acid.  
ATCUN-HH= 0.3 mM, Cu(II) = 0.3 mM,50 mM HEPES buffer pH 7.4. The 
concentration of ascorbic acid is 0.1 mM, 0.3 mM, 0.5 mM, 0.7 mM, 1 mM. The 
absorption near 390 nm increased as a function of ascorbic acid concentration. 
 
3.2.4 The effect of different reducing agents 
The previous studies show that ascorbic acid is required to generate the new 
species, the absorbance of which increases at 390 nm as the concentration of ascorbic 
acid increases. It is interesting to study whether this new species is specific to ascorbic 
acid or if it is also formed when adding other reducing agents. 
Sodium dithionite was used as an alternative reducing agent to ascorbic acid in 
these experiments. Peptide-Cu(II) (1:1, 0.3 mM) solutions with excess sodium dithionite 
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(1 mM) in 50 mM pH 7.4 HEPES were monitored by UV-Vis spectroscopy. Figure 12 
shows the comparison of ATCUN-HH and Ctr1 peptide. 
Figure 12A shows that the 525 nm absorption band of Cu(II)-ATCUN-HH does 
not change upon addition of excess sodium dithionite, while a new feature with weak 
absorbance around 370 nm grows in within the first hour. This new feature at 370 nm 
has a different appearance and λmax compared to the 390 nm feature found in the 
ascorbic acid reactions. The mutant peptides H3A and H7A/H8A under the same 
conditions also show growth of absorbance below 400 nm in the presence of sodium 
dithionite, but the feature takes slower to develop and has weaker intensity compared to 
ATCUN-HH (Appendix A.4). 
In contrast to the observations with ATCUN-HH, the 525 nm signal of Cu(II)-
Ctr1 initially loses intensity upon addition of sodium dithionite before recovering its 
original intensity over time (Figure 12B), suggesting that sodium dithionite is able to 
reduce Cu(II) to Cu(I), but over time in air reoxidation to Cu(II) reforms Cu(II)-Ctr1. 
Also unlike the ATCUN-HH example is that no few feature below 400 nm appears in 
spectra of Cu(II), Ctr1 and sodium dithionite in the presence of air. Inexplicably, the 
Cu(II)-F9AA peptide sample does not show any signs of reaction with sodium dithionite 
(Appendix A.4). The F9AA peptide does not contain any tyrosine or tryptophan residues, 
but its reactivity with Cu(II) and ascorbic acid is nearly identical to that of ATCUN-HH 
with respect to formation of the 390 nm feature. Its different reactivity with sodium 
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dithionite is therefore surprising, and further suggests that the 370 nm feature observed 
in the ATCUN-HH/dithionite reaction is unrelated to the 390 nm feature observed in 
reactions with ascorbic acid. 
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A                                                         B 
Figure 12: UV-Vis spectra of peptide, Cu(II) in the presence of excess sodium 
dithionite. 
ATCUN-HH = 0.3 mM, Ctr1 = 0.3 mM, Cu(II) = 0.3 mM, sodium dithionite = 1 
mM, experiments conducted in 50 mM HEPES buffer pH=7.4. A) ATCUN-HH + Cu(II) + 
Na2S2O4, B) Ctr1 + Cu(II) + Na2S2O4. 
 
3.2.5 The effect of component concentrations 
In an attempt to generate a high-concentration sample of the species absorbing at 
390 nm for further spectroscopic analysis, a sample was prepared in air containing 2.4 
mM Cu(II)-ATCUN-HH and 8 mM ascorbic acid in 50 mM HEPES buffer, pH=7.4. 
Figure 13 shows the unexpected result. Instead of generating the 390 nm feature at 
higher intensity, a strong absorbance near 420 nm formed after the addition of ascorbic 
acid and this peak shifted to the left over 32 hours. Also, the absorbance band of the 
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ATCUN-Cu(II) binding site around 525 nm disappeared initially upon addition of 
ascorbic acid which initially lower the pH of the solution to about 4.8. The pH rebounds 
to 5.7 after 5 hour.  This observation suggests that the formation of new species may 
have some relationship with the pH of the solution. 
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Figure 13: UV-Vis spectrum of ATCUN-HH and Cu(II) in the presence of excess 
ascorbic acid. 
ATCUN-HH = 2.4 mM, Cu(II) = 2.4 mM, ascorbic acid = 8 mM, experiment was 
conducted in 50 mM HEPES buffer, pH=7.4. the pH of which shifted from 7.4 to 4.8 upon 
addition of ascorbic acid, then back up to 5.8 after 5 h.  
 
3.2.6 Analysis of peptide-copper binding by the oxidation of ascorbic 
acid 
The aerobic oxidation of ascorbic acid is very slow when there are no catalytic 
metal ions present. However, when redox active metal ion such as Cu or Fe is present, 
ascorbic acid will be readily oxidized (Figure 14).[41] The coordination environment 
around metal complexes can significantly attenuate the rate of metal-catalyzed ascorbate 
oxidation. Chapter 2 described Cu(II) and Cu(I) binding properties for various histidine-
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containing model peptides. The study of oxidation rate of ascorbic acid can provide an 
opportunity to integrate study the peptides-Cu binding properties.  
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Figure 14: Copper catalyzed ascorbate oxidation. [34, 41] 
 The catalytic reaction of ascorbic acid was studied by UV-Vis spectroscopy. 
Ascorbic acid has an absorbance at 265 nm in 50 mM HEPES buffer, pH=7.4. In this 
experiment, ascorbic acid = 0.1 mM, CuSO4 = 10 µM, peptide = 50 µM. The model 
peptides H3A, ATCUN-HH, H7A and H7A/H8A were tested in this experiment.   
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Figure 15: UV-Vis absorbance changes at 265 nm of 0.1 mM ascorbic acid with 
different peptides and Cu(II) in aerobic conditions, pH=7.4.  
 36 
In Figure 15, auto-oxidation of ascorbic acid in pH 7.4 is very slow, as indicated 
by the minimal decrease of A265 over time. In contrast, free Cu(II) ion can robustly 
catalyze the oxidation of ascorbic acid, as indicated by the decrease in A265 over time. 
Except for H3A peptide, ATCUN-HH, H7A/H8A and H7A can suppress the rate of 
copper catalyzed ascorbic acid. This result indicates that these peptides bind Cu in a 
coordination environment that minimizes Cu redox-cycling between Cu(II) and Cu(I) 
oxidation states. Notably, all of these peptides contain an Cu(II)-ATCUN binding site. 
However, H3A seems to slightly increase the oxidation rate in this condition compared 
to free Cu(II), suggesting that H3A binds Cu in a manner that favors its redox-cycling 
between Cu(I) and Cu(II). H3A does not contain an ATCUN-Cu(II) binding site, but 
does have some affinity for Cu(I) with its His-His site.  
3.3 Mass spectral analysis of Cu-peptide-ascorbic acid reactions 
3.3.1 LC-MS results 
In order to identify potential reaction products present in samples that show an 
absorbance band around 390 nm, LC-MS data were collected on samples of the 
Cu(II)/peptide solution and Cu(II)/peptide solution that had been incubated with 
ascorbic acid for 1 hour. Figure 16 A shows the total ion chromatogram (TIC) result for a 
Cu(II)-ATCUN-HH solution, which contains two observed peaks. The first peak that 
elutes close to the solvent front corresponds to the HEPES buffer. The peak eluting 
between 2-2.5 min provides an extracted ion chromatogram with m/z values of 760.8888, 
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507.5955 and 380.9498. These mass/charge values correspond to [P+2H]2+, [P+3H]3+ and 
[P+4H]4+, where P stands for the peptide mass ion and H is an associated proton (Figure 
16 B). The calculated mass of this species is 1519.78 Da which attributed to the free 
ATCUN-HH peptide, the theoretical mass of ATCUN-HH peptide is 1519.76 Da. Given 
the acidic nature of the chromatography elution conditions, it is not surprising to find 
apo peptide in the chromatogram, even from solutions that contained Cu initially.  
 
A 
 
B 
Figure 16: LC-MS result of ATCUN-HH with Cu(II) in 50 mM HEPES buffer pH=7.4. 
ATCUN-HH = 0.3 mM, CuSO4 = 0.3 mM. A) Total ion chromatogram resulting 
from a sample containing ATCUN-HH with Cu(II). B) Mass spectrum extracted from the 
TLC between 2-2.5 min, consistent with ATCUN-HH peptide.  
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ATCUN-HH 
+2 
+3 
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Figure 17 reveals an addition peak in the chromatogram from samples incubated 
with ascorbic acid for 1 h. The new peak eluting at 6.2 min corresponds to m/z=768.8854, 
512.9275 and 384.9476 (Figure 17 B). These values are consistent with a peptide of mass 
difference of ∆m = +15.99 Da compared to ATCUN-HH peptide. This result shows that 
solution conditions that lead to formation of the absorbing species with λmax 390 nm also 
generate some fraction of oxidized peptide. 
 
A 
 
Figure 17: LC-MS result for ATCUN-HH and Cu(II) in the presence of 1 mM ascorbic 
acid in 50 mM HEPES buffer pH=7.4. 
ATCUN-HH = 0.3 mM, Cu(II) = 0.3 mM. A) TIC of ATCUN-HH and Cu(II) with 
excess ascorbic acid. B) Extracted mass spectrum corresponding to the peak eluting at 
6.2 min in spectrum A. 
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3.3.2 MALDI study 
Matrix-assisted laser desorption/ionization (MALDI) is an ionization technique 
always used in the analysis of protein and peptide. Model peptide-Cu(II) solution in the 
presence of excess ascorbic acid were studied by MALDI. 
Table 3: MALDI result of ATCUN-HH with different concentration of Cu(II) 
in the presence of excess ascorbic acid.* 
 P P+16 P+32 P+Cu P+Cu+16 P+Cu+32 P+2Cu 
0.5 eq X   X    
0.6 eq X   X    
0.8 eq X X  X    
1 eq X X X X X  X 
1.2 eq X X X X    
1.4 eq X X X X    
1. 5 eq X X X X    
2 eq X X X X    
*ATCUN-HH = 0.3 mM, Cu(II) concentration ranged from 0.5-2 equivalents, 
ascorbic aicd = 1 mM, 50 mM HEPES buffer pH=7.4 has been used. After 1 hour MALDI 
test performed for all samples. The “X” in the table represent that the sample has this 
peak. 
 
In previous experiments we studied the effect of the stoichiometry of peptide 
and Cu(II) on the formation of the new peak around 390 nm. It suggests that when the 
ratio of ATCUN-HH to Cu(II) is approximately 1, the addition of ascorbic acid can lead 
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to the formation of the 390 peak, while much more peptide or Cu(II) cannot generate this 
peak. In order to verify the differences between each ratio, after the UV-Vis spectroscopy 
study samples were collected for MALDI. Table 3 shows that the ATCUN-HH peptide is 
oxidized except when 0.5 equivalents and 0.6 equivalents of Cu(II) is present. 
Table 4: MALDI result for different peptide with Cu(II) and ascorbic acid* 
Cu+acid P P+16 P+32 P+Cu P+Cu+16 P+Cu+32 P+2Cu 
ATCUN-HH X X  X X  X 
H3A X X  X    
H7A/H8A X   X    
Ctr1 X X X X X  X 
F9AA X X  X X  X 
* Peptide = 0.3 mM, CuSO4 = 0.3 mM, ascorbic acid = 1 mM, experiments 
conducted in 50 mM HEPES buffer pH= 7.4. MALDI data collected after all the 
components mixed for 1 hour. 
 
The effect of different reducing agent also been studied by MALDI. Table 4 
shows that except for H7A/H8A all the model peptides have an oxidation peak after the 
addition of ascorbic acid for 1 hour. There are no significant differences between 
ATCUN-HH and the other peptides. In Table 5 the addition of sodium dithionite after 1 
hour also leads to the oxidation peak formation for the model peptides. It is important to 
note that for the H7A/H8A peptide, neither ascorbic acid nor sodium dithionite can 
oxidize the peptide after 1 hour. Previous studies show that only ATCUN-HH and 
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F9AA have the absorbance near 390 nm with Cu(II) and excess ascorbic acid. However, 
this new peak is specific for ascorbic acid.  In this experiment the addition of ascorbic 
acid or sodium dithionite can oxidize all of the model peptides. MALDI analysis shows 
that the addition of ascorbic acid or sodium dithionite does not have lots differences for 
all the model peptides. It is unknown if ascorbic acid and sodium dithionite oxidize 
peptides via the same pathway.  
Table 5: MALDI result for different peptide with Cu(II) and sodium 
dithionite* 
Cu+Na2S2O4 P P+16 P+32 P+Cu P+Cu+16 P+Cu+32 P+2Cu 
ATCUN-HH X X X X X X  
H3A X X X X    
H7A/H8A X   X    
Ctr1 X X X X X   
F9AA X   X    
* Peptide = 0.3 mM, CuSO4 = 0.3 mM, sodium dithionite = 1 mM, experiments 
conducted in 50 mM HEPES buffer pH= 7.4. MALDI data collected after all the 
components mixed for 1 hour. 
 
3.4 Summary 
In this chapter, UV-Vis spectroscopy and mass spectroscopy have been utilized 
to study the new species that is formed when excess ascorbic acid is added to a Cu(II)-
ATCUN-HH solution. Based on these studies, several conclusions can be drawn. First, 
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the formation of the new species requires the presence of oxygen or another oxidizing 
agent such as hydrogen peroxide. Secondly, the stoichiometry of the ATCUN-HH 
peptide and Cu(II) can affect the formation of new species. When the ratio of peptide to 
Cu(II) is around 1 the peak at 390 nm can form. Third, it seems that the formation of the 
new species requires the presence of ascorbic acid. 
 
A 
 
B 
Figure 18: A) Structure of BA.[42]  B) UV-Vis spectrum of the generation of BACu(II)-
OOH.[42] 
An early report suggested that a short metal binding fragment of amyloid 
peptides has catechol- and phenol- oxidase like activity.[43-45] This oxidative activity 
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includes oxygen binding and form reactive intermediate by a di-Cu(II) center.[43-46] 
One study shows that Cu(II)-histatin 5 can oxidize catechol, showing enzyme-like 
kinetics.[45] Based on these precedents, the new peak near 390 nm may be related to 
copper-peroxo or copper–hydroperoxo species which are regarded as reactive 
intermediates in biological oxygenases such as dophamine β-hydroxylase.[46] Previous 
study shows that the synthesized ligand named BA can form a complex with Cu(II) 
(Figure 18A).[42] This study shows that Cu(II)-hydroperoxo species can be produced by 
the reaction of  this copper (II) complex and H2O2 in the presence of a base (Figure 
18A).[42] This Cu(II)-hydroperoxo complex has a LMCT band at 350-400 nm which is 
quite similar to the new peak in our experiment (Figure 18B).[42] In addition, the LC-MS 
and MALDI results show that the peptide has been oxidized after adding ascorbic acid 
to the Cu(II)-peptide solution.  
Figure 19 shows the hypothesis of the formation of the new species which has 
absorbance at 390 nm. Previous studies have shown that Cu(II)-histatin peptides with 
ascorbic acid can produce H2O2, which may facilitate the formation of Cu-hydroperoxo 
species.[40] It is possible that with O2 and ascorbic acid present, the Cu-ATCUN-HH 
complex rapidly forms Cu(I) species and then is oxidized to the metal-peroxo or metal-
hydroperoxo species (Figure 19). These intermediate may have absorbance near 390 nm, 
and finally lead to the oxidation of peptides. From the mass spectroscopy result it is 
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possible that the histidine residues in the sequence are oxidized. Further study is needed 
to elucidate the new peak formed in these experiments. 
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Figure 19: Hypothesis of the formation of new species which has absorbance at 
390 nm. 
P represents ATCUN-HH or F9AA peptide. After the addition of excess ascorbic 
acid, peptide-Cu(II) may formed Cu-peroxo complex and followed by peptide oxidation.  
 
3.5 Material and methods 
Material 
L-ascorbic acid, sodium dithionite and HEPES are all from Sigma-Aldrich. A 0.05 
M HPEES buffer solution was prepared by dissolving HEPES in Nanopure water. The 
pH of this solution is adjusted by 0.1 M NaOH.  
UV-Vis spectroscopy 
Absorption spectra were collected by either a Cary50 UV-Vis spectrophotometer 
or an SI Photonics (Tucson, AZ) model 420 fiber optic CCD array UV-Vis 
spectrophotometer. 
Mass Spectrometry 
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Electrospray ionization mass spectrometry (ESI-MS) were collected on an Agilent 
1100 Series spectrometer. The condition of the LC-MS is on a C-18 column with a linear 
15 minutes gradient from 0-60% acetonitrile in water with 0.1% TFA. 
MALDI study 
A saturated matrix solution was made by dissolving α-Cyano-4-
hydroxycinnamic acid in ethanol. The final samples achieved by add 9 µL matrix and 1 
µL sample solution, 1 µL of this mixture is applied to a stainless-steel sample well. 
Samples were measured by bruker Daltonics Ultraflex II TOF/TOF mass spectrometer 
(Bruker Daltonics, Billerica, MA). 
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4. Study of reactive oxygen species in vitro 
4.1 Background and significance 
The term “ Reactive oxygen species” (ROS) is used for oxygen species which 
more reactive than triplet oxygen.[47] The production of ROS such as superoxide, 
hydrogen peroxide and the hydroxyl radical are always related with metal ions such as 
Fe(II,III) and Cu(I, II).[47] ROS are often produced as unwanted byproducts of cellular 
respiration. ROS production is a source of oxidative stress and loss of the ability to 
control ROS results in oxidative damage which is related to many diseases.[47] 
Understanding of the mechanism of antifungal activity of histatin 5 is important 
if histatins are to be considered as potential candidates for drug therapy. It is know that 
the antifungal activity of histatin 5 is limited to cells that undergo cellular respiration. 
Since respiratory disorders can lead to the production of ROS, it is possible that these 
oxidative species may play a role in the antimicrobial activity of histatin5.[20] 
Moreover, previous studies about the in vitro production of ROS by histatins and 
copper suggest that high levels of hydrogen peroxide can be generated in a solution 
containing Cu(II), histatin 5 or histatin 8 and a reductant, either ascorbic acid or 
cysteine.[40] It shows that the amount of superoxide produced when histatin 5 or 
histatin 8 is present is greater than when there is no peptide present in the solution.[40] 
Therefore, when Cu(II) and histatin 5 and a reductant are present in solution, peroxide 
and superoxide can be produced. Considering that the new species discussed in chapter 
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3 may be related to ROS formation, the DCF (2 ,´7 -´dichlorofluorescein) assay is used to 
study ROS formation by histatin model peptides in this chapter. 
4.2 Results 
4.2.1 Introduction of DCF assay 
DCFDA is one of the most popular probes used to detect ROS.[48] DCFDA is 
deacetylated by NaOH to yield H2DCF (dihydrodichlorofluorescin), H2DCF is then 
added to a 96-well microtiter plate. The oxidation of this molecule to the fluorochrome 
DCF results in fluorescence.[47, 48] The fluorescense turn on indicates the presence of a 
species capable of 2-electron oxidation, which can include ROS.[47] 
 
Figure 20: Mechanism of DCF assay. 
4.2.2 Comparison of histatin model peptides 
It has been shown previously that ATCUN-HH, Cu(II) and ascorbic acid can 
generate a new species that has an absorbance band at 390 nm. However, this feature 
only occurred for the ATCUN-HH and F9AA peptides. In order to elucidate whether 
this new species is related to ROS formation and how the sequence of these peptides 
affects their redox activity, the DCF assay was performed for ATCUN-HH, H7A, H8A, 
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H7A/H8A, H3A, F9AA, Ctr1 and GlyGlyHis peptide, a short ATCUN peptide that can 
bind Cu(II).  
The Cu-catalyzed aerobic oxidation of ascorbic acid generates ROS that are 
capable of oxidizing H2DCF to fluorescent DCF. In this experiment, 40 µM CuSO4, 1 
mM ascorbic acid and 10 µM H2DCF were incubated at room temperature with 10-60 
µM concentration of each peptide and the florescence intensity was measured after 2 
hours. As a control, a well that only contained Cu(II), ascorbic acid and H2DCF was also 
measured. 
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Figure 21: Fluorescence intensity of DCF recorded 2 h after reacting model peptides, 
Cu(II) and H2DCF in the presence of excess ascorbic acid. 
In each well, Cu(II)=40 µM, ascorbic acid=1 mM, the concentration for ATCUN-
HH, Ctr1, GlyGlyHis, H7A/H8A,H7A, H8A, F9AA, H3A is 10, 20, 30, 40, 50, 60 µM in 50 
mM pH 7.4 HEPES buffer. Fluorescence intensity measured after 2 hour. 
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Figure 21 shoes the result of this experiment. In order to acquire a clear 
understanding of the results we set the intensity of the control well to 1. A bar with 
intensity greater than 1 indicates that those conditions that favor DCF oxidation over 
and above the background condition of Cu(II) alone, while an intensity less than one 
indicates that the peptide inhibits the copper-catalyzed reactions that lead to DCF 
fluorescence. Most of the peptides favored greater DCF formation than the control at 
substiochiometric concentrations with respect to Cu, then became inhibitory when the 
ratio of peptide : Cu exceed 1. When the peptide concentration is less than 40 µM, 
ATCUN-HH peptide dramatically increases the fluorescence intensity compared to 
when no peptide is present and compared to the other peptide. It is worth noting that 
the ratio of ATCUN-HH to Cu(II) can affect the fluorescence intensity. When ATCUN-
HH/Cu(II) is greater than 1, ATCUN-HH inhibits DCF fluorescence intensity. Previous 
studies in chapter 3 shows that the ratio of ATCUN-HH to Cu(II) can affect the 
absorbance of the new 390 nm species. This indicates that the new species may be 
related to ROS formation. 
The GlyGlyHis peptide, which contains only an ATCUN motif, inhibits DCF 
fluorescence at all concentration tested. It is notable that the Ctr1 peptide, which 
contains both an ATCUN and a His-His motif, also inhibits at all concentrations tested. 
In contrast, H3A which lack an ATCUN-Cu(II) site but does contain a His-His motif 
increases that ROS formation in all the conditions tested. This latter result is consistent 
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with the faster rate of ascorbate oxidation observed for H3A compared to Cu alone or 
Cu with the other peptides (Figure 15). 
4.2.3 Comparison of different reducing agents 
In order to verify the functions of different reducing agents, sodium dithionite 
was tried in the DCF assay. In this experiment, 40 µM Cu(II), 1 mM sodium dithionite 
and 10 µM H2DCF were combined in each well. For each peptide, the concentration 
ranged from 30-60 µM and the florescence intensity was measured after 2 hours. A 
control well that contained Cu(II), sodium dithionite and H2DCF was also measured. 
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Figure 22: Fluorescence intensity of DCF recorded 2 h after reacting model peptides, 
Cu(II) and H2DCF in the presence of excess sodium dithionite. 
In each well the Cu(II)=40 µM, sodium dithionite=1 mM, the concentration for 
ATCUN-HH, Ctr1, F9AA,H3A, H7A/H8A is 30, 40, 60 µM, 50 mM pH 7.4 HEPES buffer 
has been used. Fluorescence intensity collected by plate reader after 2 hours.  
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Figure 22 shows that the addition of H7A/H8A and Ctr1 peptide cannot increase 
the fluorescence intensity. When the ratio of peptide/Cu(II) is greater than 1, the 
addition of the ATCUN-HH peptide also cannot increase the fluorescence intensity. 
However, when peptide/Cu(II) is less than 1, the addition of ATCUN-HH can 
significantly increase the fluorescence intensity. This is similar to the results obtained 
when ascorbic acid is present. It is interesting that the addition of H3A can increase the 
fluorescence in all conditions which is similar to the results obtained using excess 
ascorbic acid. Therefore, in the presence of either reducing agent ATCUN-HH peptide 
promotes the Cu-catalyzed oxidation that lead to increasing the DCF fluorescence 
intensity. This indicates that the addition of ATCUN-HH generates more ROS than 
when no peptide is present. However, previous UV-Vis spectroscopy studies show that 
the addition of sodium dithionite to a Cu(II)-ATCUN-HH solution cannot generate the 
new peak near 390 nm. Based on these results, it is not clear whether the new species 
which has absorbance near 390 nm is related to the formation of ROS. 
4.3 Summary 
Previous studies show that the antifungal activity of histatin 5 may be related to 
ROS formation.[20] In this chapter, we studied ROS formation by the DCF assay. This 
study has demonstrated that DCF fluorescence is most elevated when aerobic mixtures 
of Cu and ascorbic acid are mixed with ATCUN-HH, F9AA, and H3A peptides, with 
some variation in optimal peptide : Cu ratios. On the other hand, the reaction is 
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inhibited by GlyGlyHis, Ctr1 and H7A/H8A peptides. It may be relevant to note that 
none of the inhibitory peptides generate a 390 nm absorbance peak when mixed with 
Cu(II) and ascorbic acid, whereas 2 of 3 the stimulatory peptides do. It is interesting to 
speculate whether the species giving rise to the 390 feature may also be responsible for 
H2DCF oxidation. The H3A result contradicts this hypothesis, since this peptide does not 
support formation of the 390 species. However, H3A turns over ascorbic acid much 
more efficiently than either ATCUN-HH or F9AA, both of which retard the Cu-
catalyzed oxidation of ascorbic acid. These differences in reactivity between H3A and 
both ATCUN-HH peptides suggest that their mechanisms for H2DCF oxidation may be 
different. For example, by promoting Cu(II)/Cu(I) cycling and ascorbic oxidation but not 
trapping Cu(II), H3A may promote formation of freely diffusible ROS species that 
proceed to oxidize H2DCF, whereas ATCUN-HH could generate a reactive Cu-bound 
ROS intermediate that could react with H2DCF. Either way, “ROS” are efficiently 
produced by the histatin-related peptides, Cu(II) and a reducing agent in vitro under 
near physiological conditions. It remains to be seen whether these species are 
responsible for ROS generation in vivo. 
In general, some strongly coordinating ligands such as chelating agents and 
some peptides can inhibit metal-promoted ROS generation.[49, 50] However, other 
proteins such as amyloid β[51, 52] and α-synuclein that bind copper can still produce 
ROS.[53] It seems that the ATCUN-HH-Cu(II) system is in the latter class. Our DCF 
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assay confirmed that in the presence of the ATCUN-HH peptide there is a large amount 
of ROS formed compared to when no peptide is present. This is consistent with previous 
studies. However, the coordinating ability of ascorbic acid and sodium dithionite 
indicates that complex such as Cu(peptide)(ascorbate) or Cu(peptide)(sodium 
dithionite) could be involved. 
However, there are several aspects of these studies that require further study. 
First, the ratio of ATCUN-HH to Cu(II) can affect the ROS formation. Previous studies 
show that when ATCUN-HH is in excess the absorbance at 390 nm does not form as a 
distinct peak after addition of ascorbic acid, although non-specific changes in the 
absorbance spectrum indicate molecular alternations have taken place that change the 
spectrum. It is possible that the 390 nm species forms fleetingly before extensive 
oxidative modification occurs. Secondly, it is would be important to study if ROS 
formation produced via the same pathway regardless of which reducing agent is used.  
4.4 Materials and methods 
General materials 
L-ascorbic acid, sodium dithionite, 2,7-dichlorofluorescein diacetate and HEPES 
are all from Sigma-Aldrich. 
H2DCFDA was dissolved in ethanol to give a 10 mM stock solution, this solution 
was then dilute to 1 mM by HEPES buffer (pH 7.4). 2 mL of 0.01 M NaOH was added to 
0.5 mL H2DCFDA solution and after 30 min 10 mL of 50 mM HPPES buffer was added 
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to get a 40 µM stock solution. This stock solution stored in fridge and prepared freshly 
each day.[54] 
DCF assay 
In a typical set of experiments using a 96-well assay plate, 50 µL peptide-Cu(II) 
solution was first added to a well. To start the reaction 50 µL of 2 mM ascorbic acid (or 
sodium dithionite) and 20 mM H2DCF solution in HEPES buffer was added. The 
fluorescence intensity of the well(s) was then recorded on a Perkin Elmer Victor 1420 
plate reader under room temperature. Shaking performed before measuring. 
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5. Conclusion 
The exact mechanism of the antifungal activity of histatin 5 is still under debate. 
Some studies proposed that copper binding property may play a significant role in the 
performance of antifungal activity of histatin 5.[29, 30] The present study confirmed that 
synthetic histatin 5 model peptide ATCUN-HH can bind Cu(II) at the ATCUN motif. 
The Cu(I) binding properties of model peptides have been studied by Fz competition 
assay, which indicates ATCUN-HH has significant affinity for Cu(I) via histidine 
residues. These results imply the flexibility of histatin 5 in binding Cu(II) and Cu(I) 
It is worth noting that a new species forms when excess ascorbic acid is present 
in the ATCUN-HH-Cu(II) solution. Our study shows that the formation of the new 
species requires the presence of oxidizing agents and ascorbic acid. The approximate 1:1 
ratio of peptide to Cu(II) is also critical for the generation of the new species. Moreover, 
DCF study suggests that in the presence of reducing agents, ATCUN-HH with Cu(II) 
can increase ROS formation compare to no peptide present. The current results suggest 
that the antimicrobial activity of histatin 5 may derive from its metal binding property 
and oxidative activity. Further studies are needed to investigate the nature of the new 
species. In addition, the whole sequence of histatin 5, rather than merely the ATCUN-
HH fragment should be explored for future mechanism investigation.  
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Appendix A 
A.1 Peptides with 1 equivalent CuSO4 (0.3 mM) in the presence of excess ascorbic acid 
(1 mM) in 50 mM HEPES pH=7.4. 
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A.2 Cu(I) binding study. Cu(I) concentration 20 µM, Fz concentration 50 µM, add 1, 5, 
10 equivalents peptide, 50 mM HEPES buffer pH=7.4. Experiment was conducted in 
nitrogen-filled glove box. 
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A.3 Change the ratio of Cu(II) to ATCUN-HH. ATCUN-HH=0.3 mM, ascorbic acid =1 
mM, 50 mM HEPES buffer, pH=7.4.Cu(II) concentration ranged from 0.8-1.5 
equivalents of ATCUN-HH.  
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1.4 eq                                                                 1.5 eq 
300 400 500 600 700 800
0.0
0.2
0.4
0.6
0.8
A
b
s
o
rb
a
n
c
e
Wavelength(nm)
 ATCUN-HH
 ATCUN-HH+CuII
 ACID
 ACID 30 min
 ACID 1h
 ACID 3h
 ACID 5h
 ACID 10h
 ACID 24h
300 400 500 600 700 800
0.00
0.05
0.10
0.15
0.20
A
b
s
o
rb
a
n
c
e
Wavlength(nm)
 ATCUN-HH
 ATCUN-HH+CuII
 ACID
 ACID 30 min
 ACID 1h
 ACID 2h
 ACID 4h
 ACID 6h
 ACID 15h
 ACID 24h
 
A.4 The effect of different reducing agent. Peptide (0.3 mM) and Cu(II) (0.3 mM) in 
the presence of 1 mM sodium dithionite, 50 mM HEPES buffer pH=7.4. 
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A.5 Ctr1 titrate Cu(I)(BCA)2.   
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A.6 MALDI result of ATCUN-HH with 1.2 equivalents of Cu(II) in the presence of 
excess ascorbic acid. MALDI test performed for sample collected at 1 h, 2 h, 5 h, 7 h,10 
h,24 h. 
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